These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 22186791)
1. Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Yang Y; Li J; Liu F; Huang L Mol Ther; 2012 Mar; 20(3):609-15. PubMed ID: 22186791 [TBL] [Abstract][Full Text] [Related]
2. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Li SD; Chono S; Huang L Mol Ther; 2008 May; 16(5):942-6. PubMed ID: 18388916 [TBL] [Abstract][Full Text] [Related]
3. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. Chono S; Li SD; Conwell CC; Huang L J Control Release; 2008 Oct; 131(1):64-9. PubMed ID: 18674578 [TBL] [Abstract][Full Text] [Related]
4. Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. Li SD; Chono S; Huang L J Control Release; 2008 Feb; 126(1):77-84. PubMed ID: 18083264 [TBL] [Abstract][Full Text] [Related]
5. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. Li J; Chen YC; Tseng YC; Mozumdar S; Huang L J Control Release; 2010 Mar; 142(3):416-21. PubMed ID: 19919845 [TBL] [Abstract][Full Text] [Related]
6. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. Li J; Yang Y; Huang L J Control Release; 2012 Feb; 158(1):108-14. PubMed ID: 22056915 [TBL] [Abstract][Full Text] [Related]
7. Intratumoral delivery and therapeutic efficacy of nanoparticle-encapsulated anti-tumor siRNA following intrapulmonary administration for potential treatment of lung cancer. Kanehira Y; Togami K; Ishizawa K; Sato S; Tada H; Chono S Pharm Dev Technol; 2019 Nov; 24(9):1095-1103. PubMed ID: 31204552 [TBL] [Abstract][Full Text] [Related]
8. Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer. Yang Y; Hu Y; Wang Y; Li J; Liu F; Huang L Mol Pharm; 2012 Aug; 9(8):2280-9. PubMed ID: 22686936 [TBL] [Abstract][Full Text] [Related]
10. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment. Yonenaga N; Kenjo E; Asai T; Tsuruta A; Shimizu K; Dewa T; Nango M; Oku N J Control Release; 2012 Jun; 160(2):177-81. PubMed ID: 22019557 [TBL] [Abstract][Full Text] [Related]
11. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer. Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852 [TBL] [Abstract][Full Text] [Related]
12. Enhanced delivery of siRNA to triple negative breast cancer cells in vitro and in vivo through functionalizing lipid-coated calcium phosphate nanoparticles with dual target ligands. Tang J; Howard CB; Mahler SM; Thurecht KJ; Huang L; Xu ZP Nanoscale; 2018 Mar; 10(9):4258-4266. PubMed ID: 29436549 [TBL] [Abstract][Full Text] [Related]
13. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Li SD; Chen YC; Hackett MJ; Huang L Mol Ther; 2008 Jan; 16(1):163-9. PubMed ID: 17923843 [TBL] [Abstract][Full Text] [Related]
14. Codelivery of zoledronic acid and doublestranded RNA from core-shell nanoparticles. Chen L; Ding Y; Wang Y; Liu X; Babu R; Ravis W; Yan W Int J Nanomedicine; 2013; 8():137-45. PubMed ID: 23319865 [TBL] [Abstract][Full Text] [Related]
15. Nanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. Xu Z; Wang Y; Zhang L; Huang L ACS Nano; 2014 Apr; 8(4):3636-45. PubMed ID: 24580381 [TBL] [Abstract][Full Text] [Related]
16. Preparation and Characterization of siRNA-Loaded Liposomes. Liu Y; Huang L Methods Mol Biol; 2021; 2282():159-169. PubMed ID: 33928575 [TBL] [Abstract][Full Text] [Related]
17. Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy. Wu JY; Wang ZX; Zhang G; Lu X; Qiang GH; Hu W; Ji AL; Wu JH; Jiang CP Int J Nanomedicine; 2018; 13():1265-1280. PubMed ID: 29551896 [TBL] [Abstract][Full Text] [Related]
18. Lipid-calcium phosphate nanoparticles for delivery to the lymphatic system and SPECT/CT imaging of lymph node metastases. Tseng YC; Xu Z; Guley K; Yuan H; Huang L Biomaterials; 2014 May; 35(16):4688-98. PubMed ID: 24613050 [TBL] [Abstract][Full Text] [Related]
19. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Zhang Y; Schwerbrock NM; Rogers AB; Kim WY; Huang L Mol Ther; 2013 Aug; 21(8):1559-69. PubMed ID: 23774791 [TBL] [Abstract][Full Text] [Related]
20. PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy. Xie Y; Qiao H; Su Z; Chen M; Ping Q; Sun M Biomaterials; 2014 Sep; 35(27):7978-91. PubMed ID: 24939077 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]